Barclays
LPCN icon

Barclays’s Lipocine LPCN Stock Holding History

Barclays’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.2K Buy
9,827
+415
+4% +$998 ﹤0.01% 4539
2026
Q1 		$75.2K Buy
+9,412
New +$82K ﹤0.01% 4147
2025
Q4 		– Sell
-9,412
Closed -$26.8K – 5498
2025
Q3 		$26.8K Hold
9,412
– – ﹤0.01% 4897
2025
Q2 		$29.7K Buy
+9,412
New +$30.5K ﹤0.01% 4790
2021
Q4 		– Sell
-1,416
Closed -$26K – 4494
2021
Q3 		$26K Buy
1,416
+1,003
+243% +$22.1K ﹤0.01% 4317
2021
Q2 		$10K Sell
413
-857
-67% -$20.2K ﹤0.01% 4637
2021
Q1 		$33K Buy
+1,270
New +$36.6K ﹤0.01% 4284
2020
Q3 		– Sell
-459
Closed -$10K – 5413
2020
Q2 		$10K Buy
+459
New +$5.95K ﹤0.01% 5323
2020
Q1 		– Hold
0
– – – 6331
2019
Q4 		– Sell
-3
Closed -$77 – 6610
2019
Q3 		$0 Buy
+3
New +$120 ﹤0.01% 6948
2019
Q1 		– Sell
-1,776
Closed -$39K – 7191
2018
Q4 		$39K Sell
1,776
-100
-5% -$2.32K ﹤0.01% 5597
2018
Q3 		$44K Hold
1,876
– – ﹤0.01% 6155
2018
Q2 		$41K Sell
1,876
-477
-20% -$11.4K ﹤0.01% 5756
2018
Q1 		$61K Buy
+2,353
New +$65.5K ﹤0.01% 5753
2017
Q3 		– Sell
-2,051
Closed -$140K – 6956
2017
Q2 		$140K Buy
2,051
+1,663
+429% +$108K ﹤0.01% 4662
2017
Q1 		$25K Buy
388
+285
+277% +$18.5K ﹤0.01% 5704
2016
Q4 		$7K Buy
103
+97
+1,617% +$6.14K ﹤0.01% 6029
2016
Q3 		$0 Sell
6
-17
-74% -$1.05K ﹤0.01% 6709
2016
Q2 		$1K Buy
+23
New +$3.56K ﹤0.01% 6121

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Barclays's LPCN Position: Q2 2026 in Review

Barclays increased its Lipocine (LPCN) stake by 4.4% in Q2 2026, buying an estimated $998 and bringing the position to 9,827 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4539.

Barclays first reported a position in LPCN in Q2 2016 and has held it in 18 quarters since. The position peaked at $140K in Q2 2017. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

  • Barclays held 9,827 shares of Lipocine worth $25.2K as of Q2 2026.
  • Barclays bought 415 Lipocine shares in Q2 2026, an estimated $998.
  • Lipocine made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4539 holding.
  • Barclays first reported a position in Lipocine in Q2 2016 and has held it in 18 quarters since.
  • Barclays's Lipocine position peaked at $140K in Q2 2017.
  • 36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.